Recovery of kidney function after dialysis initiation in children and adults in the US: A retrospective study of United States Renal Data System data.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
02 2021
Historique:
received: 27 01 2020
accepted: 22 01 2021
revised: 05 03 2021
pubmed: 20 2 2021
medline: 29 6 2021
entrez: 19 2 2021
Statut: epublish

Résumé

Little is known about factors associated with recovery of kidney function-and return to dialysis independence-or temporal trends in recovery after starting outpatient dialysis in the United States. Understanding the characteristics of individuals who may have the potential to recover kidney function may promote better recognition of such events. The goal of this study was to determine factors associated with recovery of kidney function in children compared with adults starting dialysis in the US. We determined factors associated with recovery of kidney function-defined as survival and discontinuation of dialysis for ≥90-day period-in children versus adults who started maintenance dialysis between 1996 and 2015 according to the United States Renal Data System (USRDS) followed through 2016 in a retrospective cohort study. We also examined temporal trends in recovery rates over the last 2 decades in this cohort. Among 1,968,253 individuals included for study, the mean age was 62.6 ± 15.8 years, and 44% were female. Overall, 4% of adults (83,302/1,953,881) and 4% of children (547/14,372) starting dialysis in the outpatient setting recovered kidney function within 1 year. Among those who recovered, the median time to recovery was 73 days (interquartile range [IQR] 43-131) in adults and 100 days (IQR 56-189) in children. Accounting for the competing risk of death, children were less likely to recover kidney function compared with adults (sub-hazard ratio [sub-HR] 0.81; 95% CI 0.74-0.89, p-value <0.001; point estimates <1 indicating increased risk for a negative outcome). Non-Hispanic black (NHB) adults were less likely to recover compared with non-Hispanic white (NHW) adults, but these racial differences were not observed in children. Of note, a steady increase in the incidence of recovery of kidney function was noted initially in adults and children between 1996 and 2010, but this trend declined thereafter. The diagnoses associated with the highest recovery rates of recovery were acute tubular necrosis (ATN) and acute interstitial nephritis (AIN) in both adults and children, where 25%-40% of patients recovered kidney function depending on the calendar year of dialysis initiation. Limitations to our study include the potential for residual confounding to be present given the observational nature of our data. In this study, we observed that discontinuation of outpatient dialysis due to recovery occurred in 4% of patients with end-stage kidney disease (ESKD) and was more common among those with ATN or AIN as the cause of their kidney disease. While recovery rates rose initially, they declined starting in 2010. Additional studies are needed to understand how to best recognize and promote recovery in patients whose potential to discontinue dialysis is high in the outpatient setting.

Sections du résumé

BACKGROUND
Little is known about factors associated with recovery of kidney function-and return to dialysis independence-or temporal trends in recovery after starting outpatient dialysis in the United States. Understanding the characteristics of individuals who may have the potential to recover kidney function may promote better recognition of such events. The goal of this study was to determine factors associated with recovery of kidney function in children compared with adults starting dialysis in the US.
METHODS AND FINDINGS
We determined factors associated with recovery of kidney function-defined as survival and discontinuation of dialysis for ≥90-day period-in children versus adults who started maintenance dialysis between 1996 and 2015 according to the United States Renal Data System (USRDS) followed through 2016 in a retrospective cohort study. We also examined temporal trends in recovery rates over the last 2 decades in this cohort. Among 1,968,253 individuals included for study, the mean age was 62.6 ± 15.8 years, and 44% were female. Overall, 4% of adults (83,302/1,953,881) and 4% of children (547/14,372) starting dialysis in the outpatient setting recovered kidney function within 1 year. Among those who recovered, the median time to recovery was 73 days (interquartile range [IQR] 43-131) in adults and 100 days (IQR 56-189) in children. Accounting for the competing risk of death, children were less likely to recover kidney function compared with adults (sub-hazard ratio [sub-HR] 0.81; 95% CI 0.74-0.89, p-value <0.001; point estimates <1 indicating increased risk for a negative outcome). Non-Hispanic black (NHB) adults were less likely to recover compared with non-Hispanic white (NHW) adults, but these racial differences were not observed in children. Of note, a steady increase in the incidence of recovery of kidney function was noted initially in adults and children between 1996 and 2010, but this trend declined thereafter. The diagnoses associated with the highest recovery rates of recovery were acute tubular necrosis (ATN) and acute interstitial nephritis (AIN) in both adults and children, where 25%-40% of patients recovered kidney function depending on the calendar year of dialysis initiation. Limitations to our study include the potential for residual confounding to be present given the observational nature of our data.
CONCLUSIONS
In this study, we observed that discontinuation of outpatient dialysis due to recovery occurred in 4% of patients with end-stage kidney disease (ESKD) and was more common among those with ATN or AIN as the cause of their kidney disease. While recovery rates rose initially, they declined starting in 2010. Additional studies are needed to understand how to best recognize and promote recovery in patients whose potential to discontinue dialysis is high in the outpatient setting.

Identifiants

pubmed: 33606673
doi: 10.1371/journal.pmed.1003546
pii: PMEDICINE-D-20-00239
pmc: PMC7935284
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1003546

Subventions

Organisme : NHLBI NIH HHS
ID : K23 HL131023
Pays : United States
Organisme : NIDDK NIH HHS
ID : K24 DK085153
Pays : United States
Organisme : NIDDK NIH HHS
ID : R03 DK111881
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000004
Pays : United States

Déclaration de conflit d'intérêts

I have read the journal’s policy and the authors of this manuscript have the following competing risks: KLJ reports membership on the Steering Committee for the GSK ASCEND clinical trials program. KDL received funding from the National Institutes of Health on acute kidney injury and is a member of the ASN and the AKI!Now workgroup.

Références

Biometrics. 2011 Mar;67(1):39-49
pubmed: 20377575
Nephron. 2015;131(3):185-90
pubmed: 26524288
N Engl J Med. 2010 Aug 12;363(7):609-19
pubmed: 20581422
Hemodial Int. 2018 Jan;22(1):66-73
pubmed: 28296033
Adv Perit Dial. 1989;5:63-6
pubmed: 2577429
J Nephrol. 2019 Jun;32(3):445-451
pubmed: 30949986
Semin Dial. 2010 Nov-Dec;23(6):606-13
pubmed: 21166875
Kidney Int. 2013 May;83(5):901-8
pubmed: 23325077
Am J Kidney Dis. 2012 Jun;59(6):829-40
pubmed: 22465328
Am J Kidney Dis. 2017 Feb;69(2):278-286
pubmed: 27940060
Crit Care. 2013 Feb 04;17(1):204
pubmed: 23394211
Nephrol Dial Transplant. 2006 May;21(5):1248-52
pubmed: 16449291
Am J Kidney Dis. 2019 Oct;74(4):523-528
pubmed: 31204193
Kidney Int. 2009 Aug;76(3):257-61
pubmed: 19455195
JAMA Intern Med. 2019 Jul 1;179(7):934-941
pubmed: 31135821
Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1859-67
pubmed: 26138260
JAMA. 1990 May 2;263(17):2344-6
pubmed: 2182918
N Engl J Med. 2012 Jul 5;367(1):20-9
pubmed: 22762315
JAMA. 2011 Aug 10;306(6):620-6
pubmed: 21828325
Fed Regist. 2003 Nov 7;68(216):63195-395
pubmed: 14610760
Nephrol Dial Transplant. 2009 Sep;24(9):2825-31
pubmed: 19443649
J Am Soc Nephrol. 2013 Jan;24(1):37-42
pubmed: 23222124
Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1868-74
pubmed: 26220818
Am J Nephrol. 2014;39(3):183-94
pubmed: 24556752
Am J Kidney Dis. 2015 Apr;65(4):592-602
pubmed: 25500361
Am J Nephrol. 2016;43(4):261-70
pubmed: 27161485
J Am Soc Nephrol. 2009 Mar;20(3):629-37
pubmed: 19158356
Kidney Int Suppl (2011). 2013 Jan;3(1):112-119
pubmed: 25599001
N Engl J Med. 2015 Nov 26;373(22):2103-16
pubmed: 26551272

Auteurs

Elaine Ku (E)

University of California San Francisco, Division of Nephrology, Department of Medicine, San Francisco, California, United States of America.
University of California San Francisco, Division of Pediatric Nephrology, Department of Pediatrics, San Francisco, California, United States of America.
University of California San Francisco, Department of Epidemiology and Biostatistics, San Francisco, California, United States of America.

Raymond K Hsu (RK)

University of California San Francisco, Division of Nephrology, Department of Medicine, San Francisco, California, United States of America.

Kirsten L Johansen (KL)

Hennepin Healthcare and University of Minnesota, Department of Medicine, Division of Nephrology, Minneapolis, Minnesota, United States of America.

Charles E McCulloch (CE)

University of California San Francisco, Department of Epidemiology and Biostatistics, San Francisco, California, United States of America.

Mark Mitsnefes (M)

Cincinnati Children's Hospital Medical Center, Department of Pediatrics, Division of Pediatric Nephrology and Hypertension, Cincinnati, Ohio, United States of America.

Barbara A Grimes (BA)

University of California San Francisco, Department of Epidemiology and Biostatistics, San Francisco, California, United States of America.

Kathleen D Liu (KD)

University of California San Francisco, Division of Nephrology, Department of Medicine, San Francisco, California, United States of America.
University of California San Francisco, Department of Anesthesia and Perioperative Care, San Francisco, California, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH